Total submissions: 10
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
ARUP Laboratories, |
RCV000508023 | SCV000605137 | likely pathogenic | not specified | 2017-04-13 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000673165 | SCV000798339 | likely pathogenic | Renal carnitine transport defect | 2018-03-09 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000673165 | SCV000953893 | pathogenic | Renal carnitine transport defect | 2024-01-04 | criteria provided, single submitter | clinical testing | This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 143 of the SLC22A5 protein (p.Pro143Leu). This variant is present in population databases (no rsID available, gnomAD 0.01%). This missense change has been observed in individual(s) with primary carnitine deficiency (PMID: 20074989, 28753539, 30863740). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 440273). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt SLC22A5 protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects SLC22A5 function (PMID: 28841266). For these reasons, this variant has been classified as Pathogenic. |
Genome- |
RCV000673165 | SCV002055803 | likely pathogenic | Renal carnitine transport defect | 2021-07-15 | criteria provided, single submitter | clinical testing | |
Giacomini Lab, |
RCV000673165 | SCV002576696 | uncertain significance | Renal carnitine transport defect | 2022-10-03 | criteria provided, single submitter | research | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000673165 | SCV002766212 | pathogenic | Renal carnitine transport defect | 2022-11-04 | criteria provided, single submitter | clinical testing | Variant summary: SLC22A5 c.428C>T (p.Pro143Leu) results in a non-conservative amino acid change located in the Major facilitator superfamily domain (IPR020846) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 8e-06 in 251496 control chromosomes (gnomAD). c.428C>T has been reported in the literature in multiple compound heterozygous and homozygous individuals affected with Primary Carnitine Deficiency, identified through newborn screening (e.g. Lee_2010, Sun_2017, Li_2022). Experimental evidence evaluating an impact on protein function demonstrated the variant significantly impairs carnitine transport activity (<10% of wild-type) (Frigeni_2017). These data indicate that the variant is very likely to be associated with disease. Six clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 and four classified it as likely pathogenic, one as pathogenic, and one as uncertain significance. Based on the evidence outlined above, the variant was classified as pathogenic. |
Fulgent Genetics, |
RCV000673165 | SCV002815104 | likely pathogenic | Renal carnitine transport defect | 2021-09-23 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000673165 | SCV004201286 | likely pathogenic | Renal carnitine transport defect | 2024-03-26 | criteria provided, single submitter | clinical testing | |
Juno Genomics, |
RCV000673165 | SCV005418400 | likely pathogenic | Renal carnitine transport defect | criteria provided, single submitter | clinical testing | PM2_Supporting+PM3_Strong+PP4+PS3_Supporting | |
Natera, |
RCV000673165 | SCV001462801 | likely pathogenic | Renal carnitine transport defect | 2020-09-16 | no assertion criteria provided | clinical testing |